Bloomberg News (3/29) reported that Medtronic Inc. artificial aortic valve system, inserted without opening the chest, “reduced patient death rates more than open-heart surgery in the first study to ever record such a finding.” The article noted that about “14 percent of patients in the 747-person trial died within a year of treatment with Medtronic’s CoreValve,” compared with “19 percent of those who underwent open-heart surgery died,” citing a study unveiled at the American College of Cardiology meeting in Washington. Bloomberg pointed out that the results “were so robust” that US regulators noted “they won’t require the standard review by outside experts before approving the device.”
Medscape (3/31) reports that Dr. David Adams of Mount Sinai Medical Center in New York presented the results, which were also published in the New England Journal of Medicine.
MedPage Today (3/31) and CardioSource (3/31) also report this story.
No comments:
Post a Comment